Researchers at the University of Colorado Boulder, CU Anschutz, and Colorado State University have developed injectable treatments that reversed osteoarthritis in animal studies within weeks, marking a potential breakthrough in regenerative medicine for one of America's most common diseases.
The work drew major federal backing this year when the Advanced Research Projects Agency for Health awarded the team up to $33.5 million to advance from animal testing toward human trials. The funding signals confidence in an approach that aims not just to manage pain but to actually repair and regenerate damaged joint tissue.
Osteoarthritis affects roughly one in six people over age 30 worldwide and ranks as the third most common disease in the United States. The condition destroys cartilage, the shock-absorbing layer between bones, eventually forcing patients to choose between pain management and joint replacement surgery. No cure exists.
Stephanie Bryant, a chemical and biological engineering professor at CU Boulder leading the research, described the acceleration from concept to animal proof in stark terms. "In two years, we were able to go from a moonshot idea to developing these therapies to demonstrating that they reverse osteoarthritis in animals," she said.
The team pursued two separate strategies. The first repurposes an existing FDA-approved drug using a custom delivery system that can be injected directly into a damaged joint, releasing medication gradually over several months. In animal testing, this approach restored joint health within four to eight weeks.
The second therapy uses engineered proteins delivered through arthroscopy that harden in place and recruit the body's own repair cells to rebuild cartilage and bone. When tested on human cells from patients needing joint replacement, the material achieved what Bryant called "full regeneration and repair of the defect."
Dr. Evalina Burger, chair of orthopedics at CU Anschutz, has watched patients lose basic function to the disease. Grandparents struggle with shoulder pain during daily tasks. Athletes abandon running, hockey, and other activities because of damaged knees or backs. The current medical gap is stark: expensive surgery or nothing.
"That's why ARPA-H is so important," Burger said, noting the rare opportunity to develop options between these extremes.
The researchers envision an affordable one-time injection for early-stage patients that protects joints for years, and rapid office-visit repairs for localized cartilage damage. Bryant said clinical trials could begin within 18 months if results continue to support the approach.
The team has founded Renovare Therapeutics Inc. to commercialize the technology and plans to publish animal study results in a peer-reviewed journal this year.
Author Jessica Williams: "If these results hold up in humans, this genuinely changes the game for millions of people stuck between pain and surgery."
Comments